EUDA Health Holdings Limited
NASDAQ:EUDAMedical - Care Facilities
+$2.20 today
- Market cap
- $53.00M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$1.79
Volume 0.04M
Average 0.02M
EUDA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
EUDA Health Holdings LimitedNASDAQ: EUDA
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue dips below year-ago levels
Q2 FY2026 cost of revenue of $1.09M fell 1.6% year over year, behind the +70.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Cost of revenue amounted to 56.1% of revenue in FY2025, down 24.9 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.6% toward the trailing-twelve-month pace of +70.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 3.83M USD
- Year-over-year change
- +17.8%
- 4-year CAGR
- +3.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.83M | +17.8% |
| FY2024 | 2024-12-31 | 3.25M | +13.4% |
| FY2023 | 2023-12-31 | 2.86M | -1.0% |
| FY2022 | 2022-12-31 | 2.89M | -12.5% |
| FY2021 | 2021-12-31 | 3.31M | — |
Cost of Revenue vs competitors
How EUDA compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +70.2% is the 3rd highest of 7, against a peer median of +11.2%.
- Cost of revenue amounts to 56.0% of revenue for EUDA, versus a peer median of 55.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $119.38M USD | -18.1% | -10.1% | 50.3% | |
| LTM Mar 2026 | $62.93M USD | +3.9% | +6.7% | 59.7% | |
| LTM Mar 2026 | $22.52M USD | +84.2% | -2.9% | 11854.7% | |
| LTM Mar 2026 | $7.48M USD | +18.5% | +4.9% | 48.8% | |
| LTM Jun 2026 | $6.82M USD | +70.2% | +9.8% | 56.0% | |
| LTM Mar 2026 | CA$4.36M CAD | +545.4% | +96.4% | 2622.4% | |
| LTM Mar 2026 | $1.37M USD | — | — | 3.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| Peer median (excluding EUDA) | — | +11.2% | +4.9% | 55.0% | |
Competitors are the stored peer set for EUDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.56M | 3.76M | 3.71M | 4.01M | 6.82M |
| Cost of Revenue | 3.31M | 2.89M | 2.86M | 3.25M | 3.83M |
| Gross Profit | 1.25M | 870K | 842.08K | 762.16K | 2.99M |
| Gross Margin | 27.4% | 23.1% | 22.7% | 19.0% | 43.9% |
| Research & Development | 129.27K | 17.21K | 0 | 0 | 249 |
| Selling, General & Admin | 1.81M | 6.75M | 4.8M | 3.34M | 5.43M |
| Operating Expenses | 1.81M | 13.09M | 4.8M | 18.1M | 5.43M |
| Depreciation & Amortization | 264.1K | 172.02K | 119.35K | 173.22K | 406.48K |
| EBITDA | 1.34M | (24.64M) | (8.29M) | (17.42M) | (2.09M) |
| EBITDA Margin | 29.4% | -654.6% | -223.7% | -434.4% | -30.7% |
| Operating Income | (559.99K) | (5.72M) | (3.96M) | (17.34M) | (2.44M) |
| Operating Margin | -12.3% | -151.9% | -106.9% | -432.2% | -35.8% |
| Interest Income | 1.92M | 0 | 0 | 0 | 0 |
| Interest Expense | 127.13K | 93.78K | 23.23K | 44.89K | 228.62K |
| Other Income / Expenses | 2.23M | (19.21M) | (4.47M) | (307.38K) | (285.26K) |
| Income Before Tax | 1.67M | (24.93M) | (8.43M) | (17.64M) | (2.73M) |
| Pre-Tax Margin | 36.6% | -662.3% | -227.6% | -439.8% | -40.0% |
| Income Tax Expense | 46.49K | (20.79K) | 0 | (4.38K) | 41.94K |
| Net Income | 864.83K | (24.88M) | (10.04M) | (15.36M) | (2.77M) |
| Net Margin | 19.0% | -661.1% | -270.9% | -382.9% | -40.7% |
| EPS (Basic) | 1.87 | (41.40) | (8.80) | (9.40) | (1.49) |
| EPS (Diluted) | 1.87 | (41.40) | (8.80) | (9.40) | (1.49) |
| Weighted Avg Shares | 462.67K | 601.48K | 1.15M | 1.62M | 1.86M |
| Weighted Avg Shares (Diluted) | 462.67K | 601.48K | 1.15M | 1.62M | 1.86M |
EUDA Health Holdings Limited
NASDAQ:EUDA
Intrinsic Alpha fair value
Locked
Current Price
$17.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.